| Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating … P Godoy, NJ Hewitt, U Albrecht, ME Andersen, N Ansari, S Bhattacharya, ... Archives of toxicology 87, 1315-1530, 2013 | 1403 | 2013 |
| Human leukocyte antigen (HLA)‐B* 57: 01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury MM Monshi, L Faulkner, A Gibson, RE Jenkins, J Farrell, CJ Earnshaw, ... Hepatology 57 (2), 727-739, 2013 | 273 | 2013 |
| The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection A Copaescu, O Smibert, A Gibson, EJ Phillips, JA Trubiano Journal of Allergy and Clinical Immunology 146 (3), 518-534. e1, 2020 | 246 | 2020 |
| Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis N Hama, R Abe, A Gibson, EJ Phillips The Journal of Allergy and Clinical Immunology: In Practice 10 (5), 1155 …, 2022 | 91 | 2022 |
| Negative regulation by PD-L1 during drug-specific priming of IL-22–secreting T cells and the influence of PD-1 on effector T cell function A Gibson, M Ogese, A Sullivan, E Wang, K Saide, P Whitaker, D Peckham, ... The Journal of Immunology 192 (6), 2611-2621, 2014 | 70 | 2014 |
| The effect of inhibitory signals on the priming of drug hapten–specific T cells that express distinct Vβ receptors A Gibson, L Faulkner, M Lichtenfels, M Ogese, Z Al-Attar, A Alfirevic, ... The Journal of Immunology 199 (4), 1223-1237, 2017 | 55 | 2017 |
| Detection of primary T cell responses to drugs and chemicals in HLA-typed volunteers: implications for the prediction of drug immunogenicity L Faulkner, A Gibson, A Sullivan, A Tailor, T Usui, A Alfirevic, ... Toxicological Sciences 154 (2), 416-429, 2016 | 54 | 2016 |
| An updated review of the diagnostic methods in delayed drug hypersensitivity A Copaescu, A Gibson, Y Li, JA Trubiano, EJ Phillips Frontiers in pharmacology 11, 573573, 2021 | 52 | 2021 |
| Dapsone‐and nitroso dapsone‐specific activation of T cells from hypersensitive patients expressing the risk allele HLA‐B* 13: 01 Q Zhao, K Alhilali, A Alzahrani, M Almutairi, J Amjad, H Liu, Y Sun, L Sun, ... Allergy 74 (8), 1533-1548, 2019 | 45 | 2019 |
| Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy BL Mangan, RK McAlister, JM Balko, DB Johnson, JJ Moslehi, A Gibson, ... British journal of clinical pharmacology 86 (9), 1778-1789, 2020 | 42 | 2020 |
| Immunopharmacogenomics: mechanisms of HLA‐associated drug reactions P Deshpande, RJ Hertzman, AM Palubinsky, JB Giles, JH Karnes, ... Clinical Pharmacology & Therapeutics 110 (3), 607-615, 2021 | 40 | 2021 |
| Immune dysregulation increases the incidence of delayed‐type drug hypersensitivity reactions DJ Naisbitt, A Olsson‐Brown, A Gibson, X Meng, MO Ogese, A Tailor, ... Allergy 75 (4), 781-797, 2020 | 32 | 2020 |
| Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗ 32: 01-positive vancomycin-induced DRESS sharing an HLA class II haplotype. N Nakkam, A Gibson, E Mouhtouris, KC Konvinse, NE Holmes, KY Chua, ... The Journal of allergy and clinical immunology 147 (1), 403-405, 2020 | 27 | 2020 |
| In Vitro Priming of Naı̈ve T-cells with p-Phenylenediamine and Bandrowski’s Base A Gibson, SH Kim, L Faulkner, J Evely, M Pirmohamed, KB Park, ... Chemical Research in Toxicology 28 (10), 2069-2077, 2015 | 27 | 2015 |
| Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions A Gibson, P Deshpande, CN Campbell, MS Krantz, E Mukherjee, ... Journal of allergy and clinical immunology 151 (2), 289-300. e4, 2023 | 23 | 2023 |
| Genomic risk factors driving immune-mediated delayed drug hypersensitivity reactions Y Li, P Deshpande, RJ Hertzman, AM Palubinsky, A Gibson, EJ Phillips Frontiers in Genetics 12, 641905, 2021 | 22 | 2021 |
| New approaches to investigate drug-induced hypersensitivity MO Ogese, S Ahmed, A Alferivic, CJ Betts, A Dickinson, L Faulkner, ... Chemical research in toxicology 30 (1), 239-259, 2017 | 22 | 2017 |
| Checkpoint inhibition reduces the threshold for drug-specific T-cell priming and increases the incidence of sulfasalazine hypersensitivity S Hammond, A Olsson-Brown, S Grice, A Gibson, J Gardner, ... Toxicological Sciences 186 (1), 58-69, 2022 | 21 | 2022 |
| Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? A Sullivan, A Gibson, BK Park, DJ Naisbitt Expert Opinion on Drug Metabolism & Toxicology 11 (3), 357-368, 2015 | 20 | 2015 |
| Development of an improved T-cell assay to assess the intrinsic immunogenicity of haptenic compounds MO Ogese, J Watkinson, A Lister, L Faulkner, A Gibson, A Hillegas, ... Toxicological Sciences 175 (2), 266-278, 2020 | 18 | 2020 |
